Precision medicine

VieCure Aligns with Oncology Care Partners to Accelerate the Adoption of Value-Based Cancer Care

Retrieved on: 
Wednesday, January 18, 2023
Technology, Health Technology, Software, Practice Management, Managed Care, Health, Data Management, Artificial Intelligence, Oncology, Algorithm, Standard of care, Family, Quality of life, Precision medicine, OCP, Partnership, Medicare, Growth, Patient, Health equity, Cancer, Multimedia, A.I, Medicine, Medical device

VieCure today announced a new strategic partnership with value-based care organization, Oncology Care Partners (“OCP”), which will assist OCP in its provision of world-class care to patients across its growing U.S. network.

Key Points: 
  • VieCure today announced a new strategic partnership with value-based care organization, Oncology Care Partners (“OCP”), which will assist OCP in its provision of world-class care to patients across its growing U.S. network.
  • This partnership will be impactful as both companies are dedicated to revolutionizing the way that cancer patients are treated.
  • OCP is committed to a new generation of cancer care, ensuring that patients are treated with “whole-person care,” giving them the opportunity to ensure the patient and family will be supported and engaged throughout the entire care process.
  • As this partnership grows, we have the opportunity to accelerate growth for both companies and, by extension, the positive impact on cancer patients,” said Joe Pietrzak, Oncology Care Partners CFO, and head of development.

North America Laboratory Animal Diets Market Report 2022: Growing Consumption of Personalized Medicines Drives Demand - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 17, 2023
Other Science, Science, End user, Animal, CRISPR, Infection, Malaria, COVID-19, HIV, Mouse, Precision medicine, Pathology, Government, Knowledge, Dengue virus, Vaccine, Genetics, Biology, Pathogen, Therapy, Drug discovery, Tissue engineering, Center for Urban and Regional Analysis, Research, Cancer, Mycobacterium tuberculosis, Île-de-France Clusters, Plasmodium falciparum, Disulfiram-like drug, Plasmodium, Regenerative medicine, Dietary supplement, Potash, Pharmaceutical industry

The North America laboratory animal diets market is segmented on the basis of diet type, animal, application, end user, and country.

Key Points: 
  • The North America laboratory animal diets market is segmented on the basis of diet type, animal, application, end user, and country.
  • Based on diet type, the North America laboratory animal diets market is segmented into standard diets, irradiated diets, and autoclavable diets.
  • Based on animal, the North America laboratory animal diets market is segmented into mouse, cat, dog, rabbit, chicken, and others.
  • Based on country, the North America laboratory animal diets market is segmented into the US, Canada, and Mexico.

Europe Medical Diagnostics Market Report 2022: Expansion of Medical Devices Industry Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Health, General Health, Immunoassay, Attention, COVID-19, POC, Synlab Group, Hematology, Pandemic, Government, Precision medicine, IVD, Coagulation, Infection, Diagnosis, Growth, Quest Diagnostics, Eurofins Scientific, Clinical chemistry, Urbanization, Sonic Healthcare, LabCorp, US, Pharmaceutical industry, Medical device

The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2023-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2023-2027)" report has been added to ResearchAndMarkets.com's offering.
  • European medical diagnostics market is expected to reach US$104.01 billion in 2027, growing at a CAGR of 4.52%, for the time period of 2023-2027.
  • Factors such as rise in number of new cancer cases, expansion of medical device industry, growth in geriatric population, accelerating demand for In-Vitro Diagnostic (IVD) and rapid urbanization would drive the growth of the market.
  • As a result of this, the demand for immunoassays is rising, which is aiding the market growth of medical diagnostics in Europe.

New Company, Velsera, Represents Summa Equity's Vision to Improve Global Health Outcomes

Retrieved on: 
Thursday, January 12, 2023
Environment, Pharmaceutical, Research, Oncology, Sustainability, Software, Finance, Medical Devices, Environmental, Social and Governance (ESG), Genetics, Professional Services, Science, Technology, Clinical Trials, Data Analytics, Biotechnology, Health, Health Technology, Unisys, Ecosystem, Algorithm, UN, Calyx, IQVIA, Laboratory, Medical imaging, Precision medicine, Machine learning, Knowledge, Health, AI, Conference, Informatics, Seven Bridges, PCR, Patient, Research, Data analysis, Innovation, Acquisition, Summa, Pharmaceutical industry, Capgemini, Pierian Spring, Parexel

The vision for Velsera is supported by thematic-focused impact fund Summa Equity (“Summa”).

Key Points: 
  • The vision for Velsera is supported by thematic-focused impact fund Summa Equity (“Summa”).
  • The promise of precision medicine is held back by barriers across routine health practice and discovery.
  • Velsera sets out to amplify the impact of clinicians, researchers and scientists for the benefit of patients around the world.
  • Velsera unites these companies to advance and bring together their missions which are centered around improving health globally through multi-omics and insights.

Biomarker Testing Services Market Size, Share & Trends Analysis Report 2022 - Growing Burden of Chronic and Infectious Diseases Supporting Demand - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Health, Biotechnology, Disease, NSCLC, Large-cell lung carcinoma, Validation, Flow cytometry, Biotechnology, Precision medicine, IQVIA, FDA, Biomarker, Amgen, Diagnosis, Patient, Prevalence, Research, Cancer, Medicine, ClinicalTrials.gov, USD, Fine chemical, Pharmaceutical industry

The "Biomarker Testing Services Market Size, Share & Trends Analysis Report by Services (Biomarker Assay Development & Validation, Flow Cytometry), by End-user (Research Institutes, CROS), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biomarker Testing Services Market Size, Share & Trends Analysis Report by Services (Biomarker Assay Development & Validation, Flow Cytometry), by End-user (Research Institutes, CROS), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research.
  • This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.
  • The biomarker assay development & validation segment by service was expected to hold the largest share of 59.8% in 2021.

CareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium

Retrieved on: 
Wednesday, January 11, 2023
Health, Hospitals, Surgery, Genetics, Research, Science, Biotechnology, Distinguishing, GEP, Digital, EST, Caregiver, Transplant surgeon, Eugene, Division, Washington University School of Medicine, DNA, Precision medicine, MD, Risk, Senior, Medical Affairs Bureau, Art, Patient, General surgery, Society, Organ transplantation, Transplant, MBA, FAST, Health, Dentistry

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced its leading participation and top spot, for the fourth consecutive year, as a Distinguished Founder’s Circle Sponsor for the 23rd Annual ASTS (American Society of Transplant Surgeons) State of the Art Winter Symposium, taking place January 12-15, in Miami, Florida.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced its leading participation and top spot, for the fourth consecutive year, as a Distinguished Founder’s Circle Sponsor for the 23rd Annual ASTS (American Society of Transplant Surgeons) State of the Art Winter Symposium, taking place January 12-15, in Miami, Florida.
  • “We take pride in our longstanding support of the American Society of Transplant Surgeons (ASTS) annual meeting, as it brings together world-class transplant leaders to drive the next wave of innovation to improve patient care,” said Reg Seeto, CEO and President of CareDx.
  • “We look forward to being part of this important meeting and sharing our latest innovations in molecular surveillance and patient-centered digital health applications.”
    CareDx will host a symposium highlighting the company’s latest scientific advancements in transplantation and digital health solutions to improve the pre- and post-transplant journey.
  • The symposium, “From Benchtop to Bedside: Clinical Utility of Multi-Modal Molecular and Digital Tools” will be held on Friday, January 13, from 11-12 noon EST.

Scipher Medicine Acquires CrossBridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time

Retrieved on: 
Tuesday, January 10, 2023
Data Management, Biotechnology, Technology, Professional Services, Managed Care, Other Health, Health, General Health, Health Technology, Data Analytics, Software, Degenerative disease, Autoimmune disease, Precision medicine, Health, Growth, Medicine, EMR, Rheumatoid arthritis, Patient, Data management, Acquisition, Software as a service, CrossBridge, Medical imaging, Pharmaceutical industry

Scipher Medicine , a precision immunology company matching each patient with their most effective therapy, has acquired Philadelphia-based data, analytics, and software company CrossBridge to bolster its data and analytics capabilities.

Key Points: 
  • Scipher Medicine , a precision immunology company matching each patient with their most effective therapy, has acquired Philadelphia-based data, analytics, and software company CrossBridge to bolster its data and analytics capabilities.
  • The acquisition gives Scipher new data management and analytics capabilities to enable a more granular and real-time understanding of patients’ treatment pathway.
  • CrossBridge’s SaaS value-based care platform bridges gaps between patients, providers, payers, and improves health outcomes and lowers the cost of care for autoimmune disease patients.
  • “To date, we have not had a platform combining critical patient molecular, clinical and claims data as autoimmune diseases, including rheumatoid arthritis.

SOPHiA GENETICS and Leading US Cancer Center Collaborate to Combine Cancer Analysis Technology for Liquid Biopsies

Retrieved on: 
Tuesday, January 10, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Genetics, Algorithm, Sophia, GENETICS, MSK, Precision medicine, Pathology, Biomarker, MD, Machine learning, Conference, Memorial Sloan Kettering Cancer Center, Research, Cancer, Clinical trial, CGP, Sophia Genetics, Neoplasm, Gold, Medical imaging, Pharmaceutical industry

This includes incorporating proprietary Comprehensive Genomic Panel (CGP) sequencing tests such as MSK-ACCESS ®, which will be commercialized by SOPHiA GENETICS as the first comprehensive ctDNA liquid biopsy test powered by the SOPHiA DDMTM Platform.

Key Points: 
  • This includes incorporating proprietary Comprehensive Genomic Panel (CGP) sequencing tests such as MSK-ACCESS ®, which will be commercialized by SOPHiA GENETICS as the first comprehensive ctDNA liquid biopsy test powered by the SOPHiA DDMTM Platform.
  • By combiningpredictive algorithms, the power of the global SOPHiA GENETICS network, and the clinical expertise of MSK in cancer genomics, experts hope to expand access to precision cancer analysis capabilities.
  • Together, SOPHiA GENETICS and MSK will collaborate to further develop MSK-ACCESS®, ensuring the solution takes advantage of the sophisticated analytics of the SOPHiA DDMTM platform.
  • The goal of the new SOPHiA CarePathTM module, paired with MSK’s CGP sequencing tests, is to help inform and improve cancer care globally.

Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Retrieved on: 
Tuesday, January 10, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Disease, Classification, Marker beacon, Doctor of Philosophy, NGS, Silicon, Precision medicine, Biomarker, Gene, Degenerative disease, Patient, Twist, Research, Cancer, Labs, Multimedia, Twist Bioscience, Martek Biosciences Corporation, Neurodegeneration, Vaccine, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20230110005063/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230110005063/en/
    Target enrichment panels enable more in-depth sequencing on target genes, reducing the need for comprehensive sequencing.
  • The panels offered through Twist will include:
    The Twist Alliance CNTG Exome Panel, which enables whole exome analysis of genetic markers relevant to rare diseases.
  • The Twist Alliance CNTG Hereditary Oncology Panel, which enables the detection of biomarkers that indicate a high risk of developing cancer.
  • “Twist Alliance panels enable research by providing access to expert-developed panels tailored to specific research areas.

Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors

Retrieved on: 
Wednesday, January 11, 2023
ACT, Disease, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Precision medicine, Breast, Colon, FDA, Lung, Genomics, Neoplasm, Food, Therapy, Patient, Physician, Pharmaceutical industry, Dietary supplement

ACTOnco is intended for use by healthcare professionals to help them inform clinical management decisions in accordance with professional guidelines for cancer patients with solid tumors.

Key Points: 
  • ACTOnco is intended for use by healthcare professionals to help them inform clinical management decisions in accordance with professional guidelines for cancer patients with solid tumors.
  • This is the first and only Asia-based company to receive FDA clearance for a comprehensive genomic profiling test.
  • ACT Genomics is the first biotech company in Asia that received market authorization for a cancer comprehensive genomic profiling assay.
  • With this incredible milestone achieved, we will continuously promote precision medicine in Asia and our company mission to turn genomics into action."